Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

BACKGROUND: Nephrotic-range proteinuria (NRP) is associated with rapid kidney function loss and increased cardiovascular (CV) disease risk. We assessed the effects of linagliptin (LINA) on CV and kidney outcomes in people with Type 2 diabetes (T2D) with or without NRP. METHODS: Cardiovascular and re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Kidney J
Hlavní autoři: Wanner, Christoph, Cooper, Mark E, Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K, Kahn, Steven E, Pfarr, Egon, Schnaidt, Sven, von Eynatten, Maximilian, George, Jyothis T, Gollop, Nicholas D, Marx, Nikolaus, Alexander, John H, Zinman, Bernard, Perkovic, Vlado
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7857804/
https://ncbi.nlm.nih.gov/pubmed/33564423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfaa225
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky